{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-010964","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.906705+00:00","generated_at":"2026-05-31T12:18:33.724163+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NeuroBo signs joint research agreement for once-monthly obesity therapy DA-1726","bullets":["Collaboration with Dong-A ST and ImmunoForge to develop long-acting formulation of GLP1R/GCGR dual agonist DA-1726.","ImmunoForge's ELP platform can extend drug half-life up to 200x, enabling once-monthly injection.","DA-1726 currently in Phase 1; financial terms of the agreement not disclosed.","Goal is to improve patient compliance and ease of administration for obesity treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-010964","json":"https://secwatch.observer/filing/0001558370-24-010964.json","markdown":"https://secwatch.observer/filing/0001558370-24-010964.md","text":"https://secwatch.observer/filing/0001558370-24-010964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024010964/0001558370-24-010964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024010964/nrbo-20240806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:18:33.724163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}